Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Gross Margin (2016 - 2025)

Historic Gross Margin for Aytu Biopharma (AYTU) over the last 12 years, with Q4 2025 value amounting to 63.46%.

  • Aytu Biopharma's Gross Margin fell 30300.0% to 63.46% in Q4 2025 from the same period last year, while for Dec 2025 it was 66.84%, marking a year-over-year decrease of 51000.0%. This contributed to the annual value of 69.04% for FY2025, which is 62100.0% down from last year.
  • Latest data reveals that Aytu Biopharma reported Gross Margin of 63.46% as of Q4 2025, which was down 30300.0% from 66.14% recorded in Q3 2025.
  • Aytu Biopharma's Gross Margin's 5-year high stood at 77.89% during Q4 2023, with a 5-year trough of 3.35% in Q1 2021.
  • In the last 5 years, Aytu Biopharma's Gross Margin had a median value of 65.5% in 2022 and averaged 60.75%.
  • As far as peak fluctuations go, Aytu Biopharma's Gross Margin plummeted by -788500bps in 2021, and later surged by 557800bps in 2022.
  • Aytu Biopharma's Gross Margin (Quarter) stood at 53.18% in 2021, then grew by 24bps to 65.81% in 2022, then increased by 18bps to 77.89% in 2023, then decreased by -15bps to 66.49% in 2024, then dropped by -5bps to 63.46% in 2025.
  • Its last three reported values are 63.46% in Q4 2025, 66.14% for Q3 2025, and 67.75% during Q2 2025.